Axelopran and Nivolumab in PD-1-Refractory Metastatic Melanoma
Axelopran and Nivolumab in PD-1-Refractory Metastatic Melanoma
Not yet recruiting · NCT07631325 · Registry updated 2026-07-13Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Axelopran and Nivolumab in PD-1-Refractory Metastatic Melanoma | Unresectable Cutaneous Melanoma | Not yet recruiting | Phase 1 / Phase 2 | 2026-07-13 | NCT07631325 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Glycyx MOR Inc. | 2 |
| John Kirkwood | 3 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| UPMC Hillman Cancer Center | Pittsburgh | United States | 330 |